Approximately 5–15% of HCC involve mutations that activate nuclear factor-erythroid factor 2-related factor 2 (NRF2) and inactivate Kelch-like ECH-associated protein 1 (KEAP1), which prevents NRF2 ubiquitination and subsequent degradation. This evidence concerns the gene NFE2L2 and hepatocellular carcinoma.